Drug Profile


Alternative Names: AG 014699; AG-14699; CO-338; PF-01367338; PF-1367338; Rubraca; Rucaparib camsylate

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Cancer Research UK
  • Developer Cancer Research UK; Clovis Oncology; Roche; UNICANCER
  • Class 3-ring heterocyclic compounds; Antineoplastics; Azepines; Indoles; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ovarian cancer
  • Phase III Fallopian tube cancer; Peritoneal cancer; Prostate cancer
  • Phase II Breast cancer; Pancreatic cancer
  • Phase I Gynaecological cancer; Solid tumours
  • Suspended Malignant melanoma

Most Recent Events

  • 15 May 2017 Phase-I clinical trials in Gynaecological cancer (Chemotherapy-induced, Late-stage disease) in United Kingdom and Australia (PO) (NCT03101280)
  • 15 May 2017 Phase-I clinical trials in Solid tumours (Late-stage disease, Combination therapy) in Australia (PO) (NCT03101280)
  • 15 May 2017 Roche initiates enrolment in a phase I trial in Solid tumours (Late-stage disease, Combination therapy) in United Kingdom (PO) (NCT03101280)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top